These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38753594)

  • 1. Macrocyclic Azapeptide Nitriles: Structure-Based Discovery of Potent SARS-CoV-2 Main Protease Inhibitors as Antiviral Drugs.
    Breidenbach J; Voget R; Si Y; Hingst A; Claff T; Sylvester K; Wolf V; Krasniqi V; Useini A; Sträter N; Ogura Y; Kawaguchi A; Müller CE; Gütschow M
    J Med Chem; 2024 Jun; 67(11):8757-8790. PubMed ID: 38753594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of macrocyclic covalent inhibitors for severe acute respiratory syndrome coronavirus 2 3CL protease.
    Tang X; Hou K; Chen X; Fan W; Wu H; Lu C; He GX
    Bioorg Med Chem; 2024 Sep; 111():117846. PubMed ID: 39106653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the Main Protease of SARS-CoV-2: From the Establishment of High Throughput Screening to the Design of Tailored Inhibitors.
    Breidenbach J; Lemke C; Pillaiyar T; Schäkel L; Al Hamwi G; Diett M; Gedschold R; Geiger N; Lopez V; Mirza S; Namasivayam V; Schiedel AC; Sylvester K; Thimm D; Vielmuth C; Phuong Vu L; Zyulina M; Bodem J; Gütschow M; Müller CE
    Angew Chem Int Ed Engl; 2021 Apr; 60(18):10423-10429. PubMed ID: 33655614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel oxazole-based macrocycles as anti-coronaviral agents targeting SARS-CoV-2 main protease.
    Al-Wahaibi LH; Mostafa A; Mostafa YA; Abou-Ghadir OF; Abdelazeem AH; Gouda AM; Kutkat O; Abo Shama NM; Shehata M; Gomaa HAM; Abdelrahman MH; Mohamed FAM; Gu X; Ali MA; Trembleau L; Youssif BGM
    Bioorg Chem; 2021 Nov; 116():105363. PubMed ID: 34555629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 M
    Citarella A; Scala A; Piperno A; Micale N
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33921886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and
    Bai B; Belovodskiy A; Hena M; Kandadai AS; Joyce MA; Saffran HA; Shields JA; Khan MB; Arutyunova E; Lu J; Bajwa SK; Hockman D; Fischer C; Lamer T; Vuong W; van Belkum MJ; Gu Z; Lin F; Du Y; Xu J; Rahim M; Young HS; Vederas JC; Tyrrell DL; Lemieux MJ; Nieman JA
    J Med Chem; 2022 Feb; 65(4):2905-2925. PubMed ID: 34242027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of inhibitors of SARS-CoV-2 papain-like protease deriving from GRL0617: Structure-activity relationships.
    Kerti L; Frecer V
    Bioorg Med Chem; 2024 Nov; 113():117909. PubMed ID: 39288705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3CL Protease Inhibitors with an Electrophilic Arylketone Moiety as Anti-SARS-CoV-2 Agents.
    Konno S; Kobayashi K; Senda M; Funai Y; Seki Y; Tamai I; Schäkel L; Sakata K; Pillaiyar T; Taguchi A; Taniguchi A; Gütschow M; Müller CE; Takeuchi K; Hirohama M; Kawaguchi A; Kojima M; Senda T; Shirasaka Y; Kamitani W; Hayashi Y
    J Med Chem; 2022 Feb; 65(4):2926-2939. PubMed ID: 34313428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, Synthesis, and Biological Evaluation of Peptidomimetic Aldehydes as Broad-Spectrum Inhibitors against Enterovirus and SARS-CoV-2.
    Dai W; Jochmans D; Xie H; Yang H; Li J; Su H; Chang D; Wang J; Peng J; Zhu L; Nian Y; Hilgenfeld R; Jiang H; Chen K; Zhang L; Xu Y; Neyts J; Liu H
    J Med Chem; 2022 Feb; 65(4):2794-2808. PubMed ID: 33872498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CL
    Han SH; Goins CM; Arya T; Shin WJ; Maw J; Hooper A; Sonawane DP; Porter MR; Bannister BE; Crouch RD; Lindsey AA; Lakatos G; Martinez SR; Alvarado J; Akers WS; Wang NS; Jung JU; Macdonald JD; Stauffer SR
    J Med Chem; 2022 Feb; 65(4):2880-2904. PubMed ID: 34347470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors.
    Huff S; Kummetha IR; Tiwari SK; Huante MB; Clark AE; Wang S; Bray W; Smith D; Carlin AF; Endsley M; Rana TM
    J Med Chem; 2022 Feb; 65(4):2866-2879. PubMed ID: 34570513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives.
    Citarella A; Dimasi A; Moi D; Passarella D; Scala A; Piperno A; Micale N
    Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of highly potent SARS-CoV-2 M
    Chen W; Feng B; Han S; Wang P; Chen W; Zang Y; Li J; Hu Y
    Bioorg Med Chem Lett; 2022 Feb; 58():128526. PubMed ID: 34998903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of SARS-CoV-2 3CL
    Wang Y; Xu B; Ma S; Wang H; Shang L; Zhu C; Ye S
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Updated Review on SARS-CoV-2 Main Proteinase (M
    Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
    Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-guided design of a perampanel-derived pharmacophore targeting the SARS-CoV-2 main protease.
    Deshmukh MG; Ippolito JA; Zhang CH; Stone EA; Reilly RA; Miller SJ; Jorgensen WL; Anderson KS
    Structure; 2021 Aug; 29(8):823-833.e5. PubMed ID: 34161756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors.
    Kitamura N; Sacco MD; Ma C; Hu Y; Townsend JA; Meng X; Zhang F; Zhang X; Ba M; Szeto T; Kukuljac A; Marty MT; Schultz D; Cherry S; Xiang Y; Chen Y; Wang J
    J Med Chem; 2022 Feb; 65(4):2848-2865. PubMed ID: 33891389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors*.
    Yang KS; Ma XR; Ma Y; Alugubelli YR; Scott DA; Vatansever EC; Drelich AK; Sankaran B; Geng ZZ; Blankenship LR; Ward HE; Sheng YJ; Hsu JC; Kratch KC; Zhao B; Hayatshahi HS; Liu J; Li P; Fierke CA; Tseng CK; Xu S; Liu WR
    ChemMedChem; 2021 Mar; 16(6):942-948. PubMed ID: 33283984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of meisoindigo derivatives as noncovalent and orally available M
    Gao Q; Liu S; Zhou Y; Fan J; Ke S; Zhou Y; Fan K; Wang Y; Zhou Y; Xia Z; Deng X
    Eur J Med Chem; 2024 Jul; 273():116498. PubMed ID: 38762916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of the potent covalent inhibitor with an acrylate warhead for SARS-CoV-2 3CL protease.
    Shen W; Chen X; Zhou L; Cheng Y; Zhang Y; Jiang X; Sun H; Shen J
    Bioorg Med Chem Lett; 2024 Nov; 112():129942. PubMed ID: 39218405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.